What question did this study set out to answer?

To investigate whether PSGL-1 functions as an immune checkpoint regulator in pancreatic ductal adenocarcinoma and determine if targeting it can overcome resistance to PD-1 immunotherapy.

May 27, 2025Open Access

Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer

View Full Paper

Ask AI

Bookmark

To investigate whether PSGL-1 functions as an immune checkpoint regulator in pancreatic ductal adenocarcinoma and determine if targeting it can overcome resistance to PD-1 immunotherapy.
Assessed PSGL-1 expression on CD8+ T cells in pancreatic ductal adenocarcinoma patients and syngeneic orthotopic mouse models.
Evaluated primary tumor growth, lung metastases, and tumor microenvironment spatial remodeling in PSGL-1-deficient (PSGL-1 -/-) mice treated with or without PD-1 blockade.
PSGL-1 deficiency resulted in T cell-dependent suppression of primary tumor growth and lung metastases alongside reduced tumor cell proliferation.
Tumors in PSGL-1-deficient mice showed increased CD8+ T cell engagement with antigen-presenting cells and an influx of pre-exhausted, stem-like CD8+ T cells.
Genetic deletion of PSGL-1 sensitized pancreatic ductal adenocarcinoma to therapeutic PD-1 blockade, producing a near-complete anti-tumor response.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Syngeneic mouse study demonstrates that disabling PSGL-1 reverses PD-1 blockade resistance in pancreatic cancer, highlighting a promising target to limit T cell exhaustion.

Cite This Study

Hope et al. (2025) studied this question.

synapsesocial.com/papers/6a85746002d378e0d14e2cf8 https://doi.org/10.1101/2025.05.22.655365

View Full Paper

Ask AI

Bookmark

Implication

Syngeneic mouse study demonstrates that disabling PSGL-1 reverses PD-1 blockade resistance in pancreatic cancer, highlighting a promising target to limit T cell exhaustion.

Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer

Key Points

Discussion

Implication

Cite This Study

Disabling PSGL-1 abrogates immune suppression and resistance to PD-1 blockade in pancreatic cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider